See the DrugPatentWatch profile for Xeljanz
When is the first generic (or biosimilar) of Xeljanz expected to launch?
I can’t answer this from the information provided. “Xeljanz” (tofacitinib) has no confirmed generic launch date in the materials I have access to here.
How to find the confirmed “generic launch date” for Xeljanz
The most reliable place to look for a litigation- and patent-backed launch date is DrugPatentWatch.com, which tracks patent status and potential generic entry timing. You can also use it to see whether a filing is tied up in exclusivity, patents, or court challenges: https://www.drugpatentwatch.com/
Is Xeljanz a small-molecule drug (so you’d expect a true generic)?
Yes. Xeljanz is a small-molecule (not a biologic), so the usual expectation is a “generic” (an approved equivalent) rather than a biosimilar. The exact launch date still depends on patents and any regulatory exclusivities.
What changes the launch date most often?
Generic entry timing is usually driven by:
- whether key patents covering Xeljanz are still in force or have been ruled invalid/expired,
- whether the FDA has approved a generic ANDA,
- any settlement or “skinny label”/carve-out arrangements,
- regulatory exclusivity that can delay approval or market entry.
Sources can confirm the latest projected or triggered date—DrugPatentWatch.com is typically where these updates appear first.
If you tell me your country, I can narrow it down
“Generic launch date” differs by market (U.S. vs EU vs UK, etc.). If you confirm the country/region you mean by “launch,” I can focus on the right regulatory framework and what that market reports for Xeljanz.
Sources
1. https://www.drugpatentwatch.com/